---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-084357"
form_type: "8-K"
ticker: "INVA"
cik: "0001080014"
company_name: "Innoviva, Inc."
filed_at: "2024-07-31T23:59:59+00:00"
generated_at: "2026-05-31T14:14:45.824521+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Innoviva Q2 2024: net loss $34.7M on investment fair-value hit; royalty revenue $67.2M

## Summary
- GSK royalty revenue $67.2M vs $65.7M YoY; net product sales $21.7M (+38% YoY).
- Net loss of $34.7M ($0.55 basic loss) due to $90.7M unfavorable change in equity investments.
- License revenue $14.5M including $8M milestone from XACDURO approval in China.
- Completed $100M share repurchase program; repurchased 0.4M shares in Q2 for $5.3M.
- XACDURO approved in China; named preferred agent in 2024 IDSA guidance; XERAVA recommended by SIS guidelines.

## SEC filing metadata
- accession: 0001104659-24-084357
- form_type: 8-K
- ticker: INVA
- cik: 0001080014
- company_name: Innoviva, Inc.
- filed_at: 2024-07-31T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1080014/000110465924084357/0001104659-24-084357-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1080014/000110465924084357/tm2420507d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-084357
- JSON: https://secwatch.observer/filing/0001104659-24-084357.json
- Plain text: https://secwatch.observer/filing/0001104659-24-084357.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.